Item 8.01 Other Events. On January 9, 2023, Entrada Therapeutics, Inc. announced the selection of clinical candidate ENTR-601-45 for the potential treatment of Duchenne muscular dystrophy patients who are Exon 45 skipping amenable. A copy of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.



99.1        Press Release issued by Entrada Therapeutics, Inc. on     J  anuary 09, 2023.

104       Cover Page Interactive Data File (embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses